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Background: The objective of this study was to evaluate the quality of life and the presence of anxiety and depres-
sion in patients with dysgeusia post halitosis treatment. 
Material and Methods: Sixty patients were divided into three groups: Dysgeusia group (DG); Halitosis group (HG) 
and Control group (CG). The following instruments were used: Medical results study Short form health research 
of 36 items (SF-36), State-state anxiety inventory (STAI) and Self-report questionnaire-20 (SRQ-20). 
Results: Of the 60 subjects studied, 85% were female and 15% were male. The evaluation of SF-36 indicated a 
statistically significant correlation between some domains for DG and showed low scores for Mental Health. In 
relation to HG, low scores were obtained for Bodily Pain, Vitality and Emotional Role. The CG showed low scores 
for Bodily Pain, General Health and Vitality. STAI was significant when DG was compared to HG and CG. The 
mean SRQ-20 score was higher in DG compared with the other groups. 
Conclusions: Persistent dysgeusia post-halitosis treatment impacts on QoL generically in the Mental health do-
main, and specifically in trait and state anxiety. Symptoms of depression were also seen in this group of patients.
 
Key words: Anxiety, depression, dysgeusia, halitosis, oral health, quality of life.
doi:10.4317/medoral.22370
http://dx.doi.org/doi:10.4317/medoral.22370
Carvalho BFC, Alves MGO, Dutra MTS, Balducci I, Nicodemo D, Almeida 
JD. Persistent dysgeusia post-halitosis treatment: How does it impact the 
patients’ quality of life? Med Oral Patol Oral Cir Bucal. 2019 May 1;24 
(3):e319-25.   
http://www.medicinaoral.com/medoralfree01/v24i3/medoralv24i3p319.pdf
Article Number: 22370          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
Med Oral Patol Oral Cir Bucal. 2019 May 1;24 (3):e319-25.                                                                                                                                             Persistent dysgeusia post-halitosis treatment
e320
Introduction
Dysgeusia is a qualitative gustatory disorder charac-
terized by a distortion in the perception of taste. Total 
dysgeusia is defined as the inability to interpret all basic 
tastes which, in most cases, is associated with mineral 
deficiency (1). This condition can cause a loss of appe-
tite and even malnutrition (2). 
The inflammation caused by radiotherapy, smoking 
habit, zinc deficiency, drugs use, medications, chlorhex-
idine mouthrinse, xerostomia and nerve damage (chorda 
tympani or glossopharyngeal) can also cause dysgeusia 
(2,3). In addition, brain tumors, as well as psychiatric, 
depression and anxiety symptoms, can be associated 
with alterations in taste (4). Heath et al. (5) demonstrat-
ed a positive correlation between average trait anxiety 
scores and bitter and salt taste thresholds. 
Dysgeusia is a symptom of difficult measurement, since 
there is no defined methodology for the determination 
of its intensity, being therefore 100% based on patient ś 
complaint. Some studies point out a significant relation-
ship between olfactory and taste disorders (2). The che-
mosensory cells and taste receptors are not limited to 
taste buds, as they can be found in airway epithelium, 
digestive tract, pancreas and brain. Retronasal olfactory 
function and olfactory nerve endings, transmit nerve 
impulses to the brain and also helps in the interpreta-
tion of the flavors, which reinforce their importance in 
this process (2).
Halitosis is a disorder characterized by unpleasant odors 
emanating from the mouth, which can have local causes 
such as carious processes, presence of a biofilm, gin-
givitis, fissured tongue, maladjusted dentures, altered 
salivary composition, tongue coating and periodontal 
diseases (6,7) or systemic causes such as sinusitis, ton-
sillitis, rhinitis, bronchitis, abscesses, gastric eruption, 
duodenal ulcer, diabetes, hormonal alterations and xe-
rostomia (8). The estimated prevalence of halitosis is 
50% in the adult population (9). In general, no specific 
difference in the prevalence or severity of halitosis is 
observed between genders, but women seem to be more 
willing to visit health professionals because of this con-
dition (10). Since halitosis is a multifactorial condition, 
treatment will depend on its origin and can be exclu-
sively local or systemic. In addition, psychological or 
psychiatric treatment is recommended in cases of pseu-
dohalitosis and halitophobia (11-13).
The microorganisms most commonly causing halitosis 
are Gram-negative anaerobic bacteria (14), that degrade 
sulfur-containing amino acids, producing volatile sulfur 
compounds (VSC) such as hydrogen sulfide (H2S), meth-
yl mercaptan (CH3SH), and dimethyl sulfide (CH3SCH3), 
which are the main compounds responsible for the foul 
odor emanating from the mouth. Other compounds such 
as butyric, propionic and valeric acid and cadaverine are 
also found, but at lower levels (6,8,10,14).
According to Yaegaki and Coil (12) halitosis has a psy-
chosomatic impact. Eli et al. (15) demonstrated that in-
dividuals with halitosis can become obsessed with their 
breath, a fact restricting social behavior and compro-
mising social interactions. Thus, in some patients, even 
though halitosis is controlled, complaining of bad breath 
persists, but actually it is related to taste alterations 
caused by disorders in patient ś gustatory perception or 
still caused by emotional disturbances (16).
The incidence of halitosis is high in the general popula-
tion and this condition has a proven psychosomatic im-
pact (11-13,15). However, there are no studies in English 
literature elucidating the direct correlation between the 
complaint of dysgeusia post-halitosis treatment. The 
studies point to dysgeusia as a factor that is often idio-
pathic or related to zinc deficiency, use of medications 
and mouthwashes with chlorhexidine (2,3). Once we 
observed in our daily practice, the trait that some halito-
sis patients after the treatment exhibited dysgeusia com-
plaint with no obvious cause, we scheduled to study this 
group separately because we hypothesized that these 
patients could have psychosomatic alterations with the 
worst quality of life (QoL). Therefore, the objective of 
the present study was to evaluate the QoL and presence 
of anxiety and depression in patients with dysgeusia af-
ter halitosis treatment.
Material and Methods
The present study was approved by the Human Re-
search Ethics Committee of the São Paulo State Uni-
versity (Unesp), Institute of Science and Technology, 
São José dos Campos (Protocol Nº. 010/2010-PH/CEP). 
A case-control study was conducted in which the sam-
ple consisted of patients seen at Unesp and at a private 
clinic specialized in halitosis treatment. Patients agreed 
to participate in the study by signing a free informed 
consent form.
- Characteristics of the sample 
Sixty patients were randomly assigned into three groups 
of 20 subjects each as follow:
1- Dysgeusia group (DG): Patients with idiopathic per-
sistent dysgeusia complaint after halitosis’ treatment. 
In this group, the halitosis was completely resolved, 
with no further emanation of VSC, confirmed by the 
portable sulfur monitor (Halimeter®, Interscan, USA). 
Patients remained with discomfort or insecurity about 
their breath due to taste alteration. Moreover, patients 
using medications, presenting periodontal disease with 
pockets larger than 3 mm, local and systemic causes 
related to breathe and taste alterations, the presence of 
Mallampati scores 3 or 4, Brodsky classification grade 3 
or 4,  and caseous tonsillitis were not included.
2- Halitosis group (HG): Patients diagnosed with halito-
sis attended in the first appointment, therefore, with un-
treated halitosis. Patients with a previous diagnosis and 
Med Oral Patol Oral Cir Bucal. 2019 May 1;24 (3):e319-25.                                                                                                                                             Persistent dysgeusia post-halitosis treatment
e321
treatment for halitosis were not included in this group. 
The organoleptic measurement was performed accord-
ing to Grigor et al. (17). It was conducted by the same 
professional previously trained on the ability to detect 
odors. In addition, VSC produced by the participants 
were measured by a portable sulphur monitor (Halime-
ter®, Interscan, USA) and the threshold limit was stated 
as 150 ppb(17).
3- Control group (CG): Patients without halitosis or dys-
geusia complaint. 
Non-inclusion criteria for all groups were the use of il-
licit drugs, confirmed thyroid disorders, radiotherapy 
and/or chemotherapy, the presence of autoimmune 
diseases, syndromes and temporomandibular joint dys-
function. The groups and its characterization are sum-
marized in figure 1. 
- Clinical treatment
All subjects were submitted to anamnesis, treatment 
plan and specific clinical tests for the VSC-producing 
bacteria and diagnosis of halitosis. 
Fig. 1. Characteristics of the samples (n=60). Dysgeusia group - DG, Halitosis group - HG, Control group - CG.
The DG received a halitosis standard treatment before 
the first appointment. This treatment consisted of den-
tal prophylaxis and oral hygiene orientation, such as the 
use of a specific tongue cleaner scraper and a tongue 
cleaner (Cetylpyridinium Chloride spray). The patients 
were also instructed to clean the nasal fossae and throat 
using warm saline irrigation when mucus was present 
in the nose or oropharynx and in the case of flu, colds 
and/or rhinitis. They also received instructions to pre-
vent prolonged fasting (hypoglycemia); to control sali-
vary flow through mechanical and gustatory stimulants 
of salivary secretion; to control water intake; to control 
the consumption of foods with high animal protein con-
tent. Post-halitosis’ treatment, the patients presented a 
complaint of persistent dysgeusia and had performed 
vitamin deficiency or insufficiency analysis. In patients 
with low serum zinc levels, supplementation was ad-
ministered because it is related to the general gustatory 
function that can affect the general mood scores in pa-
tients with dysgeusia (18).
Med Oral Patol Oral Cir Bucal. 2019 May 1;24 (3):e319-25.                                                                                                                                             Persistent dysgeusia post-halitosis treatment
e322
The HG’s patients received the same standard treatment 
for halitosis as described in DG. Since HG patients did 
not present dysgeusia complaint, no vitamin deficiency 
investigation or any supplementation was done.
- QoL Questionnaires 
The emotional profile of the subjects studied was evalu-
ated using instruments for assessment of generic and 
specific aspects of health-related QoL. The QoL ques-
tionnaires were applied as follows: in the DG, the pa-
tients answered the questionnaires after the halitosis 
treatment. In the HG, the patients answered the ques-
tionnaires before the clinical halitosis standard treat-
ment. In the CG the questionnaires were applied at the 
first appointment, after the anamnesis. The experimen-
tal design is shown in figure 2. 
Fig. 2. The experimental design. Dysgeusia group (DG), Halitosis group (HG), Control group (CG), Treatment plan (TP), Quality of life (QoL).
For all instruments, the patients only marked the an-
swers that were closest to what they considered to be 
true. The patients completed the self-administered 
questionnaires in a quiet room after instruction by the 
examiner. The following instruments were used: Medi-
cal Outcomes Study 36-Item Short Form Health Survey 
(SF-36), State-Trait Anxiety Inventory (STAI), and Self-
Reporting Questionnaire-20 (SRQ-20). 
The SF-36 is a generic questionnaire used to assess 
QoL, which emphasizes the individual’s perception of 
health in the last 4 weeks and consists of eight domains 
divided into two main groups: physical (physical func-
tioning - PF, role physical - RP, bodily pain - BP, general 
health - GH) and mental (vitality - V, social function-
ing - SF, role emotional - RE, and mental health - MH). 
The scores obtained for each domain range from 0 (poor 
health) to 100 (good health). 
The STAI is a self-report questionnaire designed to mea-
sure anxiety, which depends on the conscious reflection 
of the subject in evaluating his state of anxiety, as well 
as characteristics of his personality. The questionnaire is 
designed to measure state anxiety (transient emotional 
state) and trait anxiety (the tendency of how to respond to 
situations). The STAI consists of two 20-item scales. In 
the trait anxiety scale (STAI-T), the subjects are asked to 
indicate how they generally feel, and in the state anxiety 
scale (STAI-S) how they feel at this very moment. Scores 
of 20 to 34 indicate low anxiety, 35 to 49 moderate anxi-
ety, 50 to 64 high anxiety, and 65 to 80 very high anxiety.
The SRQ-20 was designed to screen for psycho-emotion-
al disorders at primary care services with the objective 
to detect non-psychotic diseases. The questionnaire con-
sists of 20 questions to be answered yes (1) or no (0). The 
final score is given by the sum of yes answers, with a 
score of 8 or higher indicating a state of depression. 
- Statistical analysis
Descriptive analysis of the results consisted of measures 
of central tendency (mean) and dispersion (standard de-
viation) calculation. For inferential analysis, one-factor 
analysis of variance by the Holm-Sidak test and Pear-
son’s linear correlation coefficient were used. A level of 
significance of 5% was adopted. 
Results
Of the 60 subjects studied, groups were matched for 
gender and age (± 3 years) at a proportion of 1:1 to DG 
and the variables are shown in Figure 1. 
The groups in study were compared at each domain of 
SF-36. The results of these comparisons are shown in 
Table 1. The domains with the lowest scores were vitali-
ty, role emotional and mental health in DG; bodily pain, 
vitality and role emotional in HG, and bodily pain, gen-
eral health and vitality in CG. For MH domain, ANOVA 
and Sidak’s multiple comparisons test (5%) indicated 
that DG differed from CG.
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PF 69.25 ± 28.39 72.00 ± 30.15 79.00 ± 27.46 F (2; 57) = 0.614 0.545
RP 71.25 ± 37.41 62.50 ± 40.96 76.25 ± 36.70 F (2; 57) = 0.657 0.522
BP 61.45 ± 22.03 61.45 ± 24.38 66.45 ± 20.95 F (2; 57) = 0.329 0.720
GH 65.85 ± 21.38 72.35 ± 19.51 72.05 ± 17.43 F (2; 57) = 0.708 0.497
V 57.00 ± 17.58 60.50 ± 23.16 70.00 ± 21.03 F (2; 57) = 2.108 0.131
SF 68.81 ± 21.67 75.00 ± 27.51 80.63 ± 25.80 F (2; 57) = 1.108 0.337
RE 56.66 ± 40.61 60.00 ± 44.06 80.00 ± 38.08 F (2; 57) = 1.896 0.159
MH 58.00 ± 14.77 70.60 ± 16.28 74.40 ± 20.29 F (2; 57) = 4.941 0.011*
ST
A
I STAI-S 44.15 ± 8.75 35.60 ± 5.35 37.05 ± 8.44 F (2; 57) = 7.120 0.002*





<8 n = 11 n = 15 n = 16 F(2; 39) = 0.043 0.958
2.90 ± 2.17 3.13 ± 1.92 3.13 ± 2.53
≥8 n = 9 n = 5 n = 4 F(2; 15) = 0.165 0.849
11.00 ± 3.50 10.20 ± 2.59 11.25 ± 1.71
Table 1. Comparison of groups: Descriptive statistics and results of ANOVA oneway for SF-36, STAI and SRQ-20.
Physical functioning - PF, role physical - RP, bodily pain - BP, general health - GH, vitality - V, social functioning - SF, role emotional - RE, and 
mental health - MH. *p-value<0.05.
A correlation analysis between the eight domains of SF-
36 was made. For DG patients the following domains 
were statistically significant correlated: (i) PF versus 
BP; PF versus GH; (ii) RP versus BP; (iii) RE versus BP 
and (iv) MH versus GH. The correlations coefficients of 
Pearson obtained in these cases were positive and mod-
erated.
The groups were compared for STAI instrument. The 
higher scores indicate a high level of anxiety. Higher 
scores to STAI-S and STAI-T were observed in DG 
when compared to HG and CG. The ANOVA oneway 
test was applied to STAI-S and STAI-T. A significant 
statistical difference was observed in STAI-S means be-
tween DG and the other groups (HG and CG); while for 
STAI-T, a significant statistical difference was observed 
between DG and HG (Table 1).
Depressive symptoms (scored SRQ-20 ≥ 8) were pres-
ent in 45% (9/20) in DG while, in HG in 25% (5/20). 
However, the highest mean score was observed in DG 
(6.55 ± 4.97). The lowest mean score mean scores was 
observed in CG (4.75 ± 4.08). A comparison between 
the mean values of the three groups was performed by 
the Holm-Sidak test (5%) that revealed no significant 
difference between the mean scores (Table 1).
Correlation analysis between the variables STAI and 
SRQ-20 was made for better understanding the behav-
ior of patients with anxiety and depression. Pearson’s 
correlation between the STAI-S, STAI-T and SRQ-20 
in DG showed a significant moderate positive correla-
tion between the SRQ-20 and STAI-S (r = 0.561 and p 
= 0.010 < 0.05) and between the SRQ-20 and STAI-T 
(r = 0.687 and p = 0.001 < 0.05), as well as a signifi-
cant strong positive correlation between the STAI-S and 
STAI-T (r = 0.783 and p = 0.001 < 0.05). In HG, there 
was a significant moderate positive correlation between 
the STAI-S and STAI-T (r = 0.503 and p = 0.024 < 0.05) 
and a significant strong positive correlation between the 
SRQ-20 and STAI-T (r = 0.821 and p = 0.001 < 0.05). In 
CG, a significant moderate positive correlation was ob-
served between the SRQ-20 and STAI-T (r = 0.660 and 
p = 0.002 < 0.05) and between the STAI-S and STAI-T 
(r = 0.698 and p = 0.001< 0.05), and a significant strong 
positive correlation between the SRQ-20 and STAI-S (r 
= 0.719 and p = 0.001 < 0.05).
Discussion
Dysgeusia was observed as a complaint in patients post 
halitosis treatment. To the best of our knowledge, this 
is the first study to describe this aspect and to evaluate 
the QoL in this specific group of patients. This study 
was important to understand the impact of dysgeusia on 
patients’ QoL. 
Studies investigating psychosomatic disorders in pa-
tients with dysgeusia are sparse in the international lit-
erature. In addition, many dental professionals are un-
aware of the importance of their role in the treatment of 
manifestations of dysgeusia and halitosis. 
Dysgeusia is defined as an altered sense or loss of taste, 
in which the perception of sour and bitter is affected 
first, followed by the perception of sweet and salty (5). 
Organic alterations such as atrophy of the tongue pa-
pillae are observed in cases of dysgeusia with mineral 
deficiency, particularly zinc deficiency (19). In contrast, 
most cases of halitosis originate in the oral cavity from 
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microbial putrefaction or bacterial metabolism of amino 
acids in local tissue debris, generating the strong odor 
characteristic of halitosis (6,14,23). 
However, we point out that the exclusion criteria were 
not common to the groups as each group has specific 
criteria. For the DG, it was necessary to exclude the 
use of drugs, because the literature indicates that some 
drugs may promote changes in the taste buds2. Also, 
the presence of local and systemic causes related to re-
spiratory and gustatory alterations was excluded, since 
the patients had already undergone halitosis treatment. 
In GH, there were no exclusion criteria since patients 
were beginning the halitosis treatment.
In agreement with other reports on halitosis (10,20,21) 
and dysgeusia (22), higher prevalence of dysgeusia was 
observed in women in the present study. This finding 
suggests that women are more willing to seek a profes-
sional for resolution of these oral problems. The mean 
age of the present patients with dysgeusia differs from 
Doty et al. (22) who found a lower mean age for both 
genders. The mean age of patients with halitosis was 
49.5 years. Mean ages of 35.12 years (21), 43.7 years (23) 
and 51.9 years (20) have been reported in other studies. 
When analyzing the domains of the SF-36, which is a 
generic instrument for the assessment of QoL, it should 
be remembered that each domain evaluates a different 
aspect of the individual (24): physical functioning do-
main evaluates how an individual performs daily tasks; 
the role physical domain evaluates how physical health 
interferes with habitual domestic or professional activi-
ties; the bodily pain domain indicates how much pain 
the individual experienced in the last weeks and the 
limitations imposed by it in daily living; the general 
health domain evaluates the individual’s perception of 
his own health and his expectations for the future; the 
vitality domain indicates the level of energy and dispo-
sition of the individual to perform daily tasks; the social 
functioning domain evaluates how much an individual’s 
habitual social activities are affected by his physical or 
emotional state; the role emotional domain evaluates 
how the emotional state interferes with daily domestic 
or professional activities, and the mental health domain 
evaluates how much of the time the individual feels anx-
ious and depressed or happy and calm in daily living. 
Mean SF-36 scores results for the mental health domain 
were lower in DG, indicating that the emotional state of 
these patients interferes negatively with their daily activi-
ties, a fact not observed for CG. A positive correlation was 
observed between mental health and general health status 
in DG, a finding highlighting how much these patients feel 
anxious and depressed and demonstrating the negative in-
terference with the perception of their own health. Boltong 
et al. (25) indicated the need for a better understanding of 
the problems related to altered taste and their impact on 
QoL, as well as the need for adequate assessment tools. 
The STAI has been validated for the Portuguese lan-
guage (26) and is one of the most commonly used in-
struments to quantify subjective components related to 
anxiety (27). The objective of the STAI-T is to evaluate 
how an individual copes with anxiety throughout life, 
whereas the STAI-S refers to the response to anxiety at 
the time of assessment (26).
Part of the patients of DG (n = 9, 45%) presented sig-
nificantly higher levels of anxiety in both the STAI-S 
and STAI-T. In agreement with the study of Heath et al. 
(5), a positive correlation was observed between per-
sonality trait (STAI-T) and depressive symptoms (SRQ-
20) in DG. Authors also suggested that altered taste in 
emotional disorders may reflect an actual change in the 
gustatory system.
Anxiety is a factor frequently associated with cases of 
halitosis. Settineri et al. (21) showed that patients with 
halitosis have higher trait and state anxiety scores and 
also report a higher frequency of stress-related problems. 
Zaitsu et al. (20) observed that patients with genuine 
halitosis, in whom malodor is caused by processes of pu-
trefaction in the oral cavity, have a strong trait of social 
anxiety disorders and experience difficulties in overcom-
ing their anxiety about bad breath. This finding might 
be explained by the fact that halitosis has a negative and 
direct influence on interpersonal relationships.
In the study of Miller and Naylor (28), taste alterations 
were reported by patients with disorders linked to depres-
sion. Nalcaci and Baran (29) indicated dysgeusia to be a 
symptom of major depression. These studies suggest that 
taste alterations are secondary to treatment of emotional 
disorders and not the other way around. In the present 
study, the number of patients with high SRQ-20 scores, 
i.e., subjects with depressive symptoms, was higher in 
DG. In general, patients with dysgeusia scored higher in 
this questionnaire than those of the other groups. 
Dysgeusia is an atypical and neglected symptom of 
depression and little is known about the mechanisms 
whereby anxiety and depression disorders cause taste 
disturbance (5). Tanaka et al. (19) reported the presence 
of psychological alterations in 24 (55.8%) of 43 patients 
with dysgeusia and in 48 (90.6%) of 53 patients with 
glossodynia. Taste is a key sense in the regulation of es-
sential nourishment and for overall health. Any distur-
bance in taste perception can influence appetite, body 
weight and psychological well-being, impacting the 
QoL of these patients (2).
Pseudohalitosis has been observed to be associated with 
the worst quality of life (11-13,30). Although the pres-
ent study did not establish a direct relation between, 
we suggest that pseudohalitosis and dysgeusia may be 
associated since patients with persistent dysgeusia had 
halitophobia even without VSC. Thus, other studies are 
necessary to better investigate the relationship between 
these complaints. 
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Oral sensorial complaints comprise a broad and com-
plex theme. It has a broad possibility of discussion, and 
yet, no gold standard treatment is available. It is a really 
promising field of research. In the present study, authors 
concluded that persistent dysgeusia post-halitosis treat-
ment impacts on QoL generically in the Mental health 
domains, and specifically in trait and state anxiety. 
Symptoms of depression were also seen in this group 
of patients.
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